Two cheers for Crohn's disease and periodontitis: Beta-defensin-2 as an actionable target to intervene on two clinically distinct diseases

Basit Öğe Kaydı
dc.contributor.authorKeskin, Mutlu
dc.contributor.authorZeidan-Chulia, Fares
dc.contributor.authorGürsoy, Mervi
dc.contributor.authorKononen, Eija
dc.contributor.authorRautava, Jaana
dc.contributor.authorGürsoy, Ulvi Kahraman
dc.date.accessioned2021-05-15T12:37:41Z
dc.date.available2021-05-15T12:37:41Z
dc.date.issued2015
dc.departmentDiş Hekimliği Fakültesien_US
dc.descriptionGursoy, Mervi/0000-0001-8545-6821; Gursoy, Ulvi Kahraman/0000-0002-1225-5751
dc.description.abstractRecent advances in multi-omics approaches encompassing genomics, transcriptomics, proteomics, and metabolomics offer hitherto unprecedented insights on common complex human diseases. A unique angle pertinent for both diagnostic and therapeutic sciences involves rethinking clinically distinct diseases with a view to their shared molecular targets, interactomes, and pathophysiologies. Reflecting at a scale of disease-to-disease associations might help clinicians, public health practitioners, drug and biotechnology developers, and associated knowledge industries in the current era. This review article examines the hypothesis that "Intersecting Molecular Pathways Permit Interventions on Multiple Clinical Endpoints", thus uniquely bringing together Crohn's disease and periodontitis. Furthermore, we propose a novel connector molecular target between these two ostensibly distinct diseases at a clinical level, human beta defensin (hBD)-2, and suggest pathways by which hBD-2 can conceivably connect Crohn's disease and periodontitis by virtue of regulating the innate-immune response. We conclude by emphasizing different approaches where hBD-2 can be employed as a diagnostic and therapeutic tool to improve the quality of life of susceptible individuals and minimize the economic costs of these two major global public health problems. The strategy presented here also presents potentials for targeting of multiple diseases through a unique "nodal molecular target" that "speaks to" multiple clinical endpoints.en_US
dc.identifier.doi10.1089/omi.2015.0077
dc.identifier.endpage450en_US
dc.identifier.issn1536-2310
dc.identifier.issn1557-8100
dc.identifier.issue8en_US
dc.identifier.pmid26171729
dc.identifier.scopus2-s2.0-84938331588
dc.identifier.scopusqualityQ2
dc.identifier.startpage443en_US
dc.identifier.urihttps://doi.org/10.1089/omi.2015.0077
dc.identifier.urihttps://hdl.handle.net/20.500.12939/572
dc.identifier.volume19en_US
dc.identifier.wosWOS:000359535100002
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKeskin, Mutlu
dc.language.isoen
dc.publisherMary Ann Liebert, Incen_US
dc.relation.ispartofOmics-A Journal of Integrative Biology
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCrohn's Diseaseen_US
dc.subjectPeriodontitisen_US
dc.subjectBeta-Defensin-2en_US
dc.titleTwo cheers for Crohn's disease and periodontitis: Beta-defensin-2 as an actionable target to intervene on two clinically distinct diseases
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Diş Hekimliği Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu